The Use of Gabexate Mesylate and Ulinastatin for the Prevention of Post- Endoscopic Retrograde Cholangiopancreatography Pancreatitis
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP). Only a few pharmacologic agents have been shown to have potential efficacy for the prophylactic treatment of post-ERCP pancreatitis (PEP). The aim of this study was to determine whether prophylactic gabexate and ulinastatin can decrease the incidence of PEP. Methods: From January 2005 to April 2010, 1,679 patients undergoing ERCP treatment were consecutively enrolled in the study. After selective exclusion, a total of 1,480 patients were included in the analysis. The patients were separated into 3 groups according to the prophylactic administration of gabexate (593 patients), ulinastatin (229 patients), or saline solution (658 patients) and analyzed retrospectively. The primary outcome measurements were the incidence of pancreatitis and hyperamylasemia. Results: PEP occurred in 21 of the 593 (3.5%) patients who received gabexate, 16 of the 229(7.0%) patients who received ulinastatin, and 48 of the 658(7.3%) patients who received a saline solution. The incidence of PEP was signifi cantly different between the gabexate and ulinastatin or saline solution groups (p<0.05). Conclusions:Gabexate prophylaxis is effective in preventing PEP. However,there is no difference in the benefi cial effects of the prophylactic administration of ulinastatin and a saline solution.
Abstract
Background/Aims: Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography (ERCP). Only a few pharmacologic agents have been shown to have potential efficacy for the prophylactic treatment of post-ERCP pancreatitis (PEP). The aim of this study was to determine whether prophylactic gabexate and ulinastatin can decrease the incidence of PEP. Methods: From January 2005 to April 2010, 1,679 patients undergoing ERCP treatment were consecutively enrolled in the study. After selective exclusion, a total of 1,480 patients were included in the analysis. The patients were separated into 3 groups according to the prophylactic administration of gabexate (593 patients), ulinastatin (229 patients), or saline solution (658 patients) and analyzed retrospectively. The primary outcome measurements were the incidence of pancreatitis and hyperamylasemia. Results: PEP occurred in 21 of the 593 (3.5%) patients who received gabexate, 16 of the 229(7.0%) patients who received ulinastatin, and 48 of the 658(7.3%) patients who received a saline solution. The incidence of PEP was signifi cantly different between the gabexate and ulinastatin or saline solution groups (p<0.05). Conclusions:Gabexate prophylaxis is effective in preventing PEP. However,there is no difference in the benefi cial effects of the prophylactic administration of ulinastatin and a saline solution.
참고문헌 (20)
- Dumonceau JM, "European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis", Endoscopy, 42, pp.503~515 (2010)
- Cavallini G, "Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy: Italian Group", N Engl J Med, 335, pp.919~923 (1996)
- Andriulli A, "Prophylaxis of ERCPrelated pancreatitis: a randomized, controlled trial of somatostatin and gabexate mesylate", Clin Gastroenterol Hepatol, 2, pp.713~718 (2004)
- Tsujino T, "Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial", Clin Gastroenterol Hepatol, 3, pp.376~383 (2005)
- Yoo JW, "Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebocontrolled trial", Pancreas, 37, pp.366~370 (2008)
- Choi CW, "Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis", Gastrointest Endosc, 69, pp.e11~e18 (2009)
- Cotton PB, "Endoscopic sphincterotomy complications and their management: an attempt at consensus", Gastrointest Endosc, 37, pp.383~393 (1991)
- Manes G, "Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study", Gastrointest Endosc, 65, pp.982~987 (2007)
- Freeman ML, "Prevention of post-ERCP pancreatitis: a comprehensive review", Gastrointest Endosc, 59, pp.845~864 (2004)
- Testoni PA, "Preventing post-ERCP pancreatitis: where are we?", JOP, 4, pp.22~32 (2003)
- Tsujino T, "Antiproteases in preventing post-ERCP acute pancreatitis", JOP, 8(4 Suppl), pp.509~517 (2007)
- Andriulli A, "Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial", Gastrointest Endosc, 56, pp.488~495 (2002)
- Ueki T, "Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial", J Gastroenterol, 42, pp.161~167 (2007)
- Ohnishi H, "Therapeutic effects of human urinary trypsin inhibitor on acute experimental pancreatitis", Nihon Yakurigaku Zasshi, 81, pp.235~244 (1983)
- Fujishiro H, "Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study", J Gastroenterol Hepatol, 21, pp.1065~1069 (2006)
- Chen S, "Role of ulinastatin in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: the Emperor’s New Clothes or Aladdin’s Magic Lamp?", Pancreas, 39, pp.1231~1237 (2010)
- Masci E, "Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis", Am J Gastroenterol, 98, pp.2182~2186 (2003)
- Disario JA, "Endoscopic balloon dilation compared with sphincterotomy for extraction of bile duct stones", Gastroenterology, 127, pp.1291~1299 (2004)
- Ueno N, "Pancreatitis induced by endoscopic balloon sphincter dilation and changes in serum amylase levels after the procedure", Gastrointest Endosc, 49(4 Pt 1), pp.472~476 (1999)
- Sugiyama M, "Predictive factors for acute pancreatitis and hyperamylasemia after endoscopic papillary balloon dilation", Gastrointest Endosc, 57, pp.531~535 (2003)